TY - JOUR
T1 - Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities
AU - Johnson, Sindhu R
AU - Brinks, Ralph
AU - Costenbader, Karen H
AU - Daikh, David
AU - Mosca, Marta
AU - Ramsey-Goldman, Rosalind
AU - Smolen, Josef S
AU - Wofsy, David
AU - Boumpas, Dimitrios T
AU - Kamen, Diane L
AU - Jayne, David
AU - Cervera, R
AU - Costedoat-Chalumeau, Nathalie
AU - Diamond, Betty
AU - Gladman, Dafna D
AU - Hahn, Bevra
AU - Hiepe, Falk
AU - Jacobsen, Søren
AU - Khanna, Dinesh
AU - Lerstrøm, Kirsten
AU - Massarotti, Elena
AU - McCune, Joseph
AU - Ruiz-Irastorza, Guillermo
AU - Sanchez-Guerrero, Jorge
AU - Schneider, Matthias
AU - Urowitz, Murray
AU - Bertsias, George
AU - Hoyer, Bimba F
AU - Leuchten, Nicolai
AU - Tani, Chiara
AU - Tedeschi, Sara K
AU - Touma, Zahi
AU - Schmajuk, Gabriela
AU - Anic, Branimir
AU - Assan, Florence
AU - Chan, Tak Mao
AU - Clarke, Ann Elaine
AU - Crow, Mary K
AU - Czirják, László
AU - Doria, Andrea
AU - Graninger, Winfried B
AU - Halda-Kiss, Bernadett
AU - Hasni, Sarfaraz
AU - Izmirly, Peter M
AU - Jung, Michelle
AU - Kumánovics, Gábor
AU - Mariette, Xavier
AU - Padjen, Ivan
AU - Pego-Reigosa, José M
AU - Romero-Diaz, Juanita
AU - Rúa-Figueroa, Íñigo
AU - Seror, Raphaèle
AU - Stummvoll, Georg H
AU - Tanaka, Yoshiya
AU - Tektonidou, Maria G
AU - Vasconcelos, Carlos
AU - Vital, Edward M
AU - Wallace, D J
AU - Yavuz, Sule
AU - Meroni, Pier Luigi
AU - Fritzler, Marvin J
AU - Naden, Ray
AU - Dörner, Thomas
AU - Aringer, Martin
N1 - © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/10
Y1 - 2020/10
N2 - OBJECTIVES: The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 Classification Criteria for systemic lupus erythematosus (SLE) have been validated with high sensitivity and specificity. We evaluated the performance of the new criteria with regard to disease duration, sex and race/ethnicity, and compared its performance against the Systemic Lupus International Collaborating Clinics (SLICC) 2012 and ACR 1982/1997 criteria.METHODS: Twenty-one SLE centres from 16 countries submitted SLE cases and mimicking controls to form the validation cohort. The sensitivity and specificity of the EULAR/ACR 2019, SLICC 2012 and ACR 1982/1997 criteria were evaluated.RESULTS: The cohort consisted of female (n=1098), male (n=172), Asian (n=118), black (n=68), Hispanic (n=124) and white (n=941) patients; with an SLE duration of 1 to <3 years (n=196) and ≥5 years (n=879). Among patients with 1 to <3 years disease duration, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 81%). The EULAR/ACR criteria performed well in men (sensitivity 93%, specificity 96%) and women (sensitivity 97%, specificity 94%). Among women, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 83%) and better specificity than the SLICC criteria (94% vs 82%). Among white patients, the EULAR/ACR criteria had better sensitivity than the ACR criteria (95% vs 83%) and better specificity than the SLICC criteria (94% vs 83%). The EULAR/ACR criteria performed well among black patients (sensitivity of 98%, specificity 100%), and had better sensitivity than the ACR criteria among Hispanic patients (100% vs 86%) and Asian patients (97% vs 77%).CONCLUSIONS: The EULAR/ACR 2019 criteria perform well among patients with early disease, men, women, white, black, Hispanic and Asian patients. These criteria have superior sensitivity than the ACR criteria and/or superior specificity than the SLICC criteria across many subgroups.
AB - OBJECTIVES: The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 Classification Criteria for systemic lupus erythematosus (SLE) have been validated with high sensitivity and specificity. We evaluated the performance of the new criteria with regard to disease duration, sex and race/ethnicity, and compared its performance against the Systemic Lupus International Collaborating Clinics (SLICC) 2012 and ACR 1982/1997 criteria.METHODS: Twenty-one SLE centres from 16 countries submitted SLE cases and mimicking controls to form the validation cohort. The sensitivity and specificity of the EULAR/ACR 2019, SLICC 2012 and ACR 1982/1997 criteria were evaluated.RESULTS: The cohort consisted of female (n=1098), male (n=172), Asian (n=118), black (n=68), Hispanic (n=124) and white (n=941) patients; with an SLE duration of 1 to <3 years (n=196) and ≥5 years (n=879). Among patients with 1 to <3 years disease duration, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 81%). The EULAR/ACR criteria performed well in men (sensitivity 93%, specificity 96%) and women (sensitivity 97%, specificity 94%). Among women, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 83%) and better specificity than the SLICC criteria (94% vs 82%). Among white patients, the EULAR/ACR criteria had better sensitivity than the ACR criteria (95% vs 83%) and better specificity than the SLICC criteria (94% vs 83%). The EULAR/ACR criteria performed well among black patients (sensitivity of 98%, specificity 100%), and had better sensitivity than the ACR criteria among Hispanic patients (100% vs 86%) and Asian patients (97% vs 77%).CONCLUSIONS: The EULAR/ACR 2019 criteria perform well among patients with early disease, men, women, white, black, Hispanic and Asian patients. These criteria have superior sensitivity than the ACR criteria and/or superior specificity than the SLICC criteria across many subgroups.
KW - Female
KW - Humans
KW - Lupus Erythematosus, Systemic/classification
KW - Male
KW - Patient Selection
KW - Sensitivity and Specificity
KW - Severity of Illness Index
KW - epidemiology
KW - systemic lupus erythematosus
KW - lupus nephritis
KW - outcomes research
UR - http://www.scopus.com/inward/record.url?scp=85090003541&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2020-217162
DO - 10.1136/annrheumdis-2020-217162
M3 - Journal article
C2 - 32816709
SN - 0003-4967
VL - 79
SP - 1333
EP - 1339
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 10
ER -